Bioniz Therapeutics
Bioniz Therapeutics is a clinical-stage biopharmaceutical company focused on transforming drug development for immune-driven diseases through the targeted and selective modulation of cytokines. Utilizing their proprietary Multi Modal Modulation (M3) technology platform, they develop next-generation anti-cytokine therapeutics that can inhibit multiple cytokines simultaneously while maintaining normal immune function. Their mission is to address complex autoimmune and cancer-related diseases by creating innovative peptide therapeutics that selectively inhibit cytokine pathways, overcoming the limitations of current therapies.
Industries
Nr. of Employees
small (1-50)
Bioniz Therapeutics
Products
BNZ-1 (PEGylated multi-cytokine inhibitory peptide)
PEGylated peptide therapeutic designed to selectively inhibit interleukins IL-2, IL-9, and IL-15; developed and studied in Phase 1/2 clinical trials for T-cell malignancies and investigated for autoimmune dermatological indications.
BNZ-2 (multi-cytokine inhibitory peptide targeting IL-15/IL-21)
Peptide therapeutic designed to selectively inhibit IL-15 and IL-21, intended for inflammatory diseases of the gastrointestinal tract and other IL-15/IL-21 driven conditions.
BNZ-3 (orally bioavailable multi-cytokine inhibitory peptide)
Peptide candidate designed for oral administration with stability in gastric and intestinal fluids; intended to inhibit selected cytokines (IL-15/IL-21) for GI and systemic indications.
M3 Technology Platform (Multi Modal Modulation)
Discovery and design platform combining cytokine biology knowledge and computational methods to create peptide therapeutics that selectively inhibit combinations of cytokines.
BNZ-1 (PEGylated multi-cytokine inhibitory peptide)
PEGylated peptide therapeutic designed to selectively inhibit interleukins IL-2, IL-9, and IL-15; developed and studied in Phase 1/2 clinical trials for T-cell malignancies and investigated for autoimmune dermatological indications.
BNZ-2 (multi-cytokine inhibitory peptide targeting IL-15/IL-21)
Peptide therapeutic designed to selectively inhibit IL-15 and IL-21, intended for inflammatory diseases of the gastrointestinal tract and other IL-15/IL-21 driven conditions.
BNZ-3 (orally bioavailable multi-cytokine inhibitory peptide)
Peptide candidate designed for oral administration with stability in gastric and intestinal fluids; intended to inhibit selected cytokines (IL-15/IL-21) for GI and systemic indications.
M3 Technology Platform (Multi Modal Modulation)
Discovery and design platform combining cytokine biology knowledge and computational methods to create peptide therapeutics that selectively inhibit combinations of cytokines.
Expertise Areas
- Peptide therapeutics discovery
- Cytokine biology and immunology
- Clinical trial management and design
- Translational medicine and clinical pharmacology
Key Technologies
- Peptide-based multi-cytokine inhibitors
- PEGylation
- In silico machine learning for drug design
- Receptor-interface structure-guided design